ARQT — Arcutis Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1787306 ·
Last close
$24.78
Market Cap
$3.11B
52W High
$29.84
52W Low
$20.48
ADV30
1,553,644
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 129,861,000 | 118,922,000 | 16,429,000 | 15,009,000 | 488,537,000 | 34,121,000 | 267,958,000 |
| Mar 2026 | 105,398,000 | 95,614,000 | -9,089,000 | -11,295,000 | 460,003,000 | 34,762,000 | 270,355,000 |
| Dec 2025 | 129,503,000 | 117,815,000 | 18,387,000 | 17,395,000 | 432,973,000 | 42,907,000 | 243,494,000 |
| Sep 2025 | 99,219,000 | 90,534,000 | 8,526,000 | 7,410,000 | 370,977,000 | 47,120,000 | 212,904,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$39,309,000
Investing CF
$-85,982,000
Financing CF
$8,255,000
CapEx
$-15,686,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.21
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,134,370,000
Inventory
$38,879,000
Receivables
$155,162,000
ST Investments
$204,431,000
EBIT TTM
$43,144,000
Pretax Income TTM
$29,298,000
Interest Exp TTM
$13,846,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$463,980,992
EBITDA
$36,503,000
Free Cash Flow
$21,685,376
Enterprise Value
$2,990,231,808
Total Cash
$238,552,000
Total Debt
$114,137,000
Shares Out
125,691,961
Trailing EPS
$0.22
Book Value
$1.76
ROE
15.9%
ROA
5.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 376,072,000 | -12,227,000 | -16,141,000 | 432,973,000 | 243,494,000 | — | -5,625,000 |
| Dec 2024 | 196,542,000 | -128,397,000 | -140,039,000 | 348,889,000 | 191,348,000 | — | -112,158,000 |
| Dec 2023 | 59,606,000 | -241,101,000 | -262,140,000 | 341,365,000 | 252,698,000 | — | -247,057,000 |
| Dec 2022 | 3,686,000 | -301,627,000 | -311,458,000 | 449,274,000 | 239,693,000 | — | -257,715,000 |
TTM Snapshot
Revenues TTM
$83,589,000
NetIncome TTM
$-250,991,000
OpCashFlow TTM
$0
Assets (Latest)
$348,889,000
Forward EPS
$1.30
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IRON | Disc Medicine, Inc. | $3.11B | $80.94 | — |
| IMNM | Immunome Inc. | $3.18B | $28.01 | — |
| MBX | MBX Biosciences, Inc. | $3.20B | $66.39 | — |
| NAMS | NewAmsterdam Pharma Co N.V. | $3.21B | $26.85 | — |
| ALMS | ALUMIS INC. | $2.98B | $23.03 | — |
News headlines (Yahoo Finance, 1h cache)
Arcutis (ARQT) Q2 2026 Earnings Call Transcript
2026-08-12 21:28 · Yahoo
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
2026-08-06 12:50 · Yahoo
Arcutis Biotherapeutics Inc (ARQT) (Q2 2026) Earnings Call Highlights: Revenue Surges 59% and ...
2026-08-06 05:08 · Yahoo
Arcutis Biotherapeutics Q2 Earnings Call Highlights
2026-08-05 22:03 · Yahoo
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates
2026-08-05 21:10 · Yahoo
Arcutis Biotherapeutics (ARQT) Heads Into Earnings With Its ZORYVE Story Still Shaping Valuation
2026-07-31 06:08 · Yahoo
Arcutis Expands Board of Directors with Appointment of Chris Peetz
2026-07-16 13:00 · Yahoo
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
2026-08-24 20:01 · Yahoo
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-07 20:00 · Yahoo
Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Call Summary
2026-08-06 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.